Product Development Strategy - The company aims to develop a comprehensive product line covering "internal medicine + surgery," "equipment + consumables," and "diagnosis + treatment" [2] - Future product development will focus on four main lines: ultrasound, digestive and respiratory products, minimally invasive surgical products, and cardiovascular products [2][3] Ultrasound Product Line - The new generation ultrasound platform launched in 2023 will be officially promoted in 2024, featuring advanced imaging technologies and AI capabilities [2] - The company plans to introduce a new generation of obstetric ultrasound on the new platform to enhance brand influence in the specialized ultrasound field [3] Digestive and Respiratory Product Line - The company has released various endoscopic products, including ultrasound endoscopes and bronchoscopes, providing comprehensive solutions for digestive and respiratory diseases [3] - Future iterations will aim to close the gap with top imported products and enhance brand influence in both domestic and global markets [3] Minimally Invasive Surgical Product Line - The company offers unique solutions such as 4K endoscopic systems and digital operating rooms, differentiating itself from domestic competitors [3] - Upcoming products will include the second generation of 4K rigid endoscopes and various surgical instruments [3] Cardiovascular Product Line - The IVUS (Intravascular Ultrasound) product was launched in 2023 and has received positive market feedback, with plans to expand investment in the cardiovascular field [4] - The domestic IVUS market is estimated to be worth several billion RMB, with significant growth potential due to increasing demand [4] Market Position and Future Outlook - The company has installed soft endoscopic products in over 400 tertiary hospitals, indicating strong market acceptance and growth potential [4] - The recent health commission's inspection plan is expected to purify the industry environment, favoring competitive brands and solidifying their market position [5]
开立医疗(300633) - 2024年1月8-12日投资者关系活动记录表